chr3-37025559-A-G
Variant names:
Variant summary
Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1
The NM_000249.4(MLH1):c.1039-78A>G variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.45 in 709,402 control chromosomes in the GnomAD database, including 78,548 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★★).
Frequency
Genomes: 𝑓 0.36 ( 10133 hom., cov: 24)
Exomes 𝑓: 0.47 ( 68415 hom. )
Consequence
MLH1
NM_000249.4 intron
NM_000249.4 intron
Scores
2
Clinical Significance
Conservation
PhyloP100: -1.10
Publications
12 publications found
Genes affected
MLH1 (HGNC:7127): (mutL homolog 1) The protein encoded by this gene can heterodimerize with mismatch repair endonuclease PMS2 to form MutL alpha, part of the DNA mismatch repair system. When MutL alpha is bound by MutS beta and some accessory proteins, the PMS2 subunit of MutL alpha introduces a single-strand break near DNA mismatches, providing an entry point for exonuclease degradation. The encoded protein is also involved in DNA damage signaling and can heterodimerize with DNA mismatch repair protein MLH3 to form MutL gamma, which is involved in meiosis. This gene was identified as a locus frequently mutated in hereditary nonpolyposis colon cancer (HNPCC). [provided by RefSeq, Aug 2017]
MLH1 Gene-Disease associations (from GenCC):
- Lynch syndromeInheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: G2P, ClinGen, Orphanet
- Lynch syndrome 2Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Ambry Genetics, Genomics England PanelApp
- Muir-Torre syndromeInheritance: AD Classification: DEFINITIVE, STRONG, MODERATE, SUPPORTIVE Submitted by: Genomics England PanelApp, Ambry Genetics, G2P, Orphanet
- mismatch repair cancer syndrome 1Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Ambry Genetics, G2P, Labcorp Genetics (formerly Invitae), Orphanet, ClinGen
- Lynch syndrome 1Inheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
- ovarian cancerInheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
- malignant pancreatic neoplasmInheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
- rhabdomyosarcomaInheritance: AR Classification: MODERATE Submitted by: Genomics England PanelApp
- prostate cancerInheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
- breast cancerInheritance: AD Classification: NO_KNOWN Submitted by: Ambry Genetics
- hereditary breast carcinomaInheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -20 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.95).
BP6
Variant 3-37025559-A-G is Benign according to our data. Variant chr3-37025559-A-G is described in ClinVar as Benign. ClinVar VariationId is 89625.Status of the report is reviewed_by_expert_panel, 3 stars.
BA1
GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.451 is higher than 0.05.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.360 AC: 50413AN: 139848Hom.: 10131 Cov.: 24 show subpopulations
GnomAD3 genomes
AF:
AC:
50413
AN:
139848
Hom.:
Cov.:
24
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.472 AC: 268833AN: 569542Hom.: 68415 AF XY: 0.469 AC XY: 133530AN XY: 284888 show subpopulations
GnomAD4 exome
AF:
AC:
268833
AN:
569542
Hom.:
AF XY:
AC XY:
133530
AN XY:
284888
show subpopulations
African (AFR)
AF:
AC:
2021
AN:
10176
American (AMR)
AF:
AC:
2349
AN:
5932
Ashkenazi Jewish (ASJ)
AF:
AC:
3696
AN:
8522
East Asian (EAS)
AF:
AC:
1735
AN:
14114
South Asian (SAS)
AF:
AC:
3433
AN:
11746
European-Finnish (FIN)
AF:
AC:
3940
AN:
9292
Middle Eastern (MID)
AF:
AC:
569
AN:
1500
European-Non Finnish (NFE)
AF:
AC:
241739
AN:
485744
Other (OTH)
AF:
AC:
9351
AN:
22516
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.567
Heterozygous variant carriers
0
5227
10454
15681
20908
26135
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Exome Het
Exome Hom
Variant carriers
0
7516
15032
22548
30064
37580
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome AF: 0.360 AC: 50411AN: 139860Hom.: 10133 Cov.: 24 AF XY: 0.353 AC XY: 23806AN XY: 67346 show subpopulations
GnomAD4 genome
AF:
AC:
50411
AN:
139860
Hom.:
Cov.:
24
AF XY:
AC XY:
23806
AN XY:
67346
show subpopulations
African (AFR)
AF:
AC:
7974
AN:
36726
American (AMR)
AF:
AC:
5437
AN:
13638
Ashkenazi Jewish (ASJ)
AF:
AC:
1386
AN:
3396
East Asian (EAS)
AF:
AC:
378
AN:
4854
South Asian (SAS)
AF:
AC:
1029
AN:
4574
European-Finnish (FIN)
AF:
AC:
2711
AN:
7234
Middle Eastern (MID)
AF:
AC:
87
AN:
256
European-Non Finnish (NFE)
AF:
AC:
30246
AN:
66370
Other (OTH)
AF:
AC:
679
AN:
1910
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.546
Heterozygous variant carriers
0
1380
2761
4141
5522
6902
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
470
940
1410
1880
2350
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
621
AN:
3424
ClinVar
Significance: Benign
Submissions summary: Benign:4
Revision: reviewed by expert panel
LINK: link
Submissions by phenotype
not provided Benign:2
Mar 03, 2015
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided
- -
not specified Benign:1
-
Mayo Clinic Laboratories, Mayo Clinic
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:research
- -
Lynch syndrome Benign:1
Sep 05, 2013
International Society for Gastrointestinal Hereditary Tumours (InSiGHT)
Significance:Benign
Review Status:reviewed by expert panel
Collection Method:research
MAF >1% -
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.